Literature DB >> 28003648

Cardiac structural remodeling in hypertensive cardiomyopathy.

Si-Jia Sun1, Jia-Lu Yao1,2, Lang-Biao Xu1, Qing Rui1, Nan-Nan Zhang1, Min Chen1, Yu-Feng Jiang1, Hua-Jia Yang1, Ya-Feng Zhou1.   

Abstract

Heart failure with preserved ejection fraction (HFpEF), which is a primary driver of morbidity and mortality, accounts for approximately half of all heart failure cases. Therefore, it is essential to develop preclinical animal models for HFpEF pharmacological treatment strategies. We created a porcine model of severe hypertension and hyperlipidemia by using a combination of deoxycorticosterone acetate (DOCA, 100 mg kg-1), Western diet (WD) and angiotensin II infusion. Systolic blood pressure, echocardiography and invasive pressure-volume loop were assessed at baseline, 12 weeks and 18 weeks. A detailed histological assessment was also performed to determine the cardiac structural remodeling. Compared with controls (n=10), hypertensive animals (n=10) showed markedly higher systolic blood pressure (181 vs. 86 mm Hg) at 18 weeks. Concentric remodeling, characterized by a normal chamber size with a thicker wall, was observed in hypertensive animals. Left ventricle diastolic function showed a tendency toward decline, according to the echocardiographic data. Hemodynamic data showed that the end-diastolic pressure-volume relationship was elevated without changes in the end-systolic pressure-volume relationship. Histological results revealed that the fibrotic area in hypertensive animals (P<0.05 vs. controls) and the fibrotic area in the posterior wall of hypertensive animals' left atria were larger than other sites of the left atria (P<0.05 vs. other sites). This model can mimic clinical HFpEF to some degree. We found that the posterior wall of the left atrium is more susceptible to atrial remodeling associated with hypertension compared with other regions of the left atrium.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28003648     DOI: 10.1038/hr.2016.169

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  22 in total

1.  Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel?

Authors:  Dirk J van Veldhuisen; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2012-11-28       Impact factor: 15.534

2.  Ventricular structure and function in aged dogs with renal hypertension: a model of experimental diastolic heart failure.

Authors:  Vijaya K Munagala; Chari Y T Hart; John C Burnett; Donna M Meyer; Margaret M Redfield
Journal:  Circulation       Date:  2005-02-21       Impact factor: 29.690

3.  Progression of left ventricular diastolic dysfunction and risk of heart failure.

Authors:  Garvan C Kane; Barry L Karon; Douglas W Mahoney; Margaret M Redfield; Veronique L Roger; John C Burnett; Steven J Jacobsen; Richard J Rodeheffer
Journal:  JAMA       Date:  2011-08-24       Impact factor: 56.272

4.  Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction.

Authors:  Venkatesh Y Anjan; Timothy M Loftus; Michael A Burke; Nausheen Akhter; Gregg C Fonarow; Mihai Gheorghiade; Sanjiv J Shah
Journal:  Am J Cardiol       Date:  2012-06-07       Impact factor: 2.778

Review 5.  Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.

Authors:  Barry A Borlaug; Walter J Paulus
Journal:  Eur Heart J       Date:  2010-12-07       Impact factor: 29.983

6.  Alterations in electrophysiology and tissue structure of the left atrial posterior wall in a canine model of atrial fibrillation caused by chronic atrial dilatation.

Authors:  Min Tang; Shu Zhang; Qi Sun; Congxin Huang
Journal:  Circ J       Date:  2007-10       Impact factor: 2.993

7.  B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure.

Authors:  Yoshitaka Iwanaga; Isao Nishi; Shinichi Furuichi; Teruo Noguchi; Kazuhiro Sase; Yasuki Kihara; Yoichi Goto; Hiroshi Nonogi
Journal:  J Am Coll Cardiol       Date:  2006-01-26       Impact factor: 24.094

8.  Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction.

Authors:  Stephan Dorfs; Wolfgang Zeh; Willibald Hochholzer; Nikolaus Jander; Rolf-Peter Kienzle; Burkert Pieske; Franz Josef Neumann
Journal:  Eur Heart J       Date:  2014-08-26       Impact factor: 29.983

9.  Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.

Authors:  Amil M Shah; Sanjiv J Shah; Inder S Anand; Nancy K Sweitzer; Eileen O'Meara; John F Heitner; George Sopko; Guichu Li; Susan F Assmann; Sonja M McKinlay; Bertram Pitt; Marc A Pfeffer; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2013-11-18       Impact factor: 8.790

10.  A porcine model of hypertensive cardiomyopathy: implications for heart failure with preserved ejection fraction.

Authors:  Michael Schwarzl; Nazha Hamdani; Sebastian Seiler; Alessio Alogna; Martin Manninger; Svetlana Reilly; Birgit Zirngast; Alexander Kirsch; Paul Steendijk; Jochen Verderber; David Zweiker; Philipp Eller; Gerald Höfler; Silvia Schauer; Kathrin Eller; Heinrich Maechler; Burkert M Pieske; Wolfgang A Linke; Barbara Casadei; Heiner Post
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-04       Impact factor: 5.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.